XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company are functioned through the United States, Europe, and Asia Pacific. XOMA's primary source of revenue is from license and collaboration arrangements, contract services, and royalties.